GM-10134

GM-10134 is a small molecule inhibitor of pyruvate dehydrogenase kinase (PDHK), developed by JD Bioscience. Its mechanism of action involves inhibiting PDHK, an enzyme that regulates the activity of the pyruvate dehydrogenase complex and plays a role in cellular metabolism. By inhibiting PDHK, GM-10134 may modulate metabolic pathways relevant to disease states such as pancreatitis and heart disease. The drug has been investigated primarily for indications including pancreatitis, sepsis, and cardiovascular diseases. As of June 2025, its highest development status is preclinical; it has not entered clinical trials or received regulatory approval[1][2][3].